May 15th 2024
The trial evaluates OCU410ST, a modifier gene therapy candidate utilizing an AAV delivery platform for the retinal delivery of the RORA gene.
(COPE Credit) Community Practice Connection™: Paradigm Shifts in Presbyopia – Understanding Advances in Topical Treatment Innovations
View More
(CME Credit) Learning About the Lid – Optimizing Recognition, Diagnosis, and Treatment of Demodex Blepharitis & Blepharoptosis
View More
2nd Annual IKA Keratoconus Symposium: Front to Back and Everything in Between
May 18-19, 2024
Register Now!
(COPE Credit) Learning About the Lid – Optimizing Recognition, Diagnosis, and Treatment of Demodex Blepharitis & Blepharoptosis
View More
(COPE Credit) Clinical Crossroads: Navigating Neurotrophic Keratitis – The Importance of Avoiding Pitfalls and Ensuring Early Intervention
View More
(CME Credit) Virtual Case Studies™ in Cataract Surgery: Selecting Surgical Techniques and Preventing Intra-Operative Complications
View More
Neurotrophic Keratitis Management: How Early Intervention Can Make a Difference
View More
(CME Credit) Clinical Crossroads: Navigating Neurotrophic Keratitis – The Importance of Avoiding Pitfalls and Ensuring Early Intervention
View More
17th Annual Controversies in Modern Eye Care
View More
Thyroid Eye Disease: The Masquerading Eye Disorder—A Guide to Collaborative Care and Accurate Diagnosis
View More
(COPE Credit) Community Practice Connections™: Advances in Geographic Atrophy – Optimizing Diagnosis, Monitoring Progression, and Increasing Communication with Transformative Treatment on the Horizon
View More
(CME Credit) Community Practice Connections™: Multidisciplinary Perspectives on Saving Sight—The Expanding Role of the Optometrist in Retinal Disease Care
View More
(CME Credit) Community Practice Connections™: Advances in Geographic Atrophy – Optimizing Diagnosis, Monitoring Progression, and Increasing Communication with Transformative Treatment on the Horizon
View More
(COPE Credit) Community Practice Connections™: Keeping an Eye on Evolving Management Strategies for nAMD and DME
View More
(COPE Credit) Community Practice Connections™: Multidisciplinary Perspectives on Saving Sight—The Expanding Role of the Optometrist in Retinal Disease Care
View More
(CME Credit) Community Practice Connections™: Keeping an Eye on Evolving Management Strategies for nAMD and DME
View More
The Ins and Outs of Lubricating Eye Drops
View More
What’s New in MGD Beyond Heating and Squeezing?
View More
Addressing Healthcare Inequities™ in Glaucoma Management – Understanding Challenges in Segmented Patient Populations (CME Track)
View More
Community Practice Connections™: Expert Perspectives in Diabetic Macular Edema – Considering Pathogenesis & Inflammation in Treatment Selection
View More
Community Practice Connections™: Novel Treatment Strategies in the Management of nAMD & DME - Lessons from Clinical Trial and Real-World Data
View More
Medical Crossfire®: Considerations for the Use of Biosimilars in Retinal Disease - Are You Prepared for a New Paradigm? (CME Credit)
View More
Medical Crossfire®: Expert Insights in Anti-VEGF Dosing for nAMD and DME – Optimizing Reduction in Treatment Burden
View More
Medical Crossfire®: Considerations for the Use of Biosimilars in Retinal Disease - Are You Prepared for a New Paradigm? (COPE Credit)
View More
EyeCon 2024
September 27-28, 2024
Register Now!
Heading to AAO? You’re invited to a CME dinner. Or join virtually!
Date TBA
Register Now!
(CME) Community Practice Connections™: A Closer Look at Neurotrophic Keratitis—Ensuring Timely Diagnosis and Taking Early Action
View More
Community Practice Connections™: Mastering the Multidisciplinary Management of Glaucoma—Understanding Advances in the Spectrum of Treatment Innovation (CME/CNE Credit)
View More
(COPE) Community Practice Connections™: A Closer Look at Neurotrophic Keratitis—Ensuring Timely Diagnosis and Taking Early Action
View More
Community Practice Connections™: Mastering the Multidisciplinary Management of Glaucoma—Understanding Advances in the Spectrum of Treatment Innovation (COPE Credit)
View More
Curing genetic blindness with space-enhanced artificial retinas
December 13th 2023LambdaVision seeks to cure genetic blindness with a protein-based artificial retina. Harnessing microgravity in low-Earth orbit, the company collaborates with NASA and the ISS to perfect its manufacturing process.
Read More
EyeCon 2023: Reducing patients' retinal burden of care
December 8th 2023David A. Eichenbaum, MD, highlighted new therapies such as faricimab and high-dose aflibercept to reduce the burden of diseases like macular degeneration and diabetic eye conditions while improving patient outcomes during his presentation at EyeCon 2023.
Read More
Study: Fish-like genetic program used to turn human Müller glia cells into neurons
December 6th 2023Fish have the built-in ability to regenerate retinal neurons by turning another retinal cell type called Müller glia into neurons. Researchers have been able to coax the human Müller glia into changing identity in the laboratory, which could serve as a potential source of new neurons to treat vision loss.
Read More
EyeCon 2023: Dr Marta Stevanovic wins Best in Retina in Visionary in Eye Care Awards program
December 2nd 2023Marta Stevanovic, MD, Massachusetts Eye and Ear, Harvard Medical School, Boston, was honored as the recipient of the inaugural Visionary in Eye Care Resident Recognition Award for the category of Best in Retina during the EyeCon 2023 conference, December 1-2, at the Marriott Sanibel Harbour Resort and Spa in Sanibel, Florida.
Read More
AAO 2023: Retinal visualization and patients who've had small aperture IOL implantation
November 21st 2023Mark Blecher, MD, spoke with the Ophthalmology Times team about his poster addressing retinal visualization and patients who've had small aperture IOL implantation at this year's American Academy of Ophthalmology meeting.
Watch
Caroline Baumal, Chief Medical Officer at Apellis, spoke with Ophthalmology Times on the GALE extension study of pegcetacoplan for geographic atrophy, and shared insights on her career transition, emphasizing the significance of mentorship and a passion for one’s work at this year's American Academy of Ophthalmology meeting in San Francisco.
Read More
The company presented topline Phase I/II first-in-human results at the 127th American Academy of Ophthalmology annual meeting in San Francisco, demonstrating significant improvement in visual field, in concordance with trended improvements in visual acuity and functional vision.
Read More
AAO 2023: OTT166 progress: OcuTerra's diabetic retinopathy treatment
November 3rd 2023Kerrie Brady, president and chief executive officer of OcuTerra Therapeutics, shares progress in their Phase 2 DR:EAM Diabetic Retinopathy study, with promising results expected in Q1 2024 for their innovative eye drop treatment, OTT166.
Read More